What is HC Wainwright’s Estimate for FDMT FY2029 Earnings?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – HC Wainwright issued their FY2029 EPS estimates for 4D Molecular Therapeutics in a report issued on Monday, January 13th. HC Wainwright analyst M. Caufield expects that the company will post earnings of ($1.81) per share for the year. HC Wainwright currently has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.89) per share.

A number of other research analysts have also commented on FDMT. Leerink Partners lowered their price target on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research report on Monday. Royal Bank of Canada reduced their price target on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. BMO Capital Markets cut 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $40.00 to $15.00 in a research note on Monday. Morgan Stanley reduced their price target on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research note on Monday. Finally, Chardan Capital reissued a “buy” rating and set a $39.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $38.56.

4D Molecular Therapeutics Trading Up 2.5 %

FDMT stock opened at $4.88 on Wednesday. The stock has a market capitalization of $225.59 million, a price-to-earnings ratio of -1.71 and a beta of 2.81. The firm’s 50-day moving average price is $6.87 and its two-hundred day moving average price is $11.77. 4D Molecular Therapeutics has a 12-month low of $4.68 and a 12-month high of $36.25.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Hedge funds have recently bought and sold shares of the business. nVerses Capital LLC purchased a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter valued at about $40,000. Values First Advisors Inc. purchased a new stake in 4D Molecular Therapeutics during the third quarter valued at $57,000. Quest Partners LLC lifted its stake in shares of 4D Molecular Therapeutics by 17,409.1% in the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock valued at $121,000 after purchasing an additional 5,745 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of 4D Molecular Therapeutics by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock worth $108,000 after purchasing an additional 3,922 shares during the period. Finally, Proficio Capital Partners LLC bought a new position in shares of 4D Molecular Therapeutics during the 3rd quarter valued at approximately $108,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.